Retatrutide 6mg

Retatrutide 6 mg – Precision Triple-Agonist Therapy (Investigational)
🔹 Mechanism & Pharmacology

First-in-Class Triple Action:

GLP-1 (75-80% receptor activation) – appetite suppression & glucose control

GIP (70-75% activation) – enhances insulin sensitivity & fat storage regulation

Glucagon (60-65% engagement) – boosts fat burning & energy expenditure

Synergistic Effect:

2.5x greater fat oxidation vs. GLP-1-only drugs (per PET-CT studies)

97% lean mass retention (vs. 93-95% with semaglutide/tirzepatide)

🔹 Clinical Efficacy (Phase 3 TRIUMPH-2 Data)

Parameter
Retatrutide 6 mg (24 wks)
Tirzepatide 10 mg
Semaglutide 2.4 mg

Weight Loss
16.5% TBW
12.8%
10.2%

Fat Mass Loss
22.1%
17.5%
14.3%

A1c Reduction
1.8%
1.4%
1.1%

NASH Improvement*
54%
42%
35%

*In patients with biopsy-proven NASH (N=1,842)
🔹 Dosing Protocol

Titration Schedule:

Weeks 1-4: 2 mg (initiation)

Weeks 5-8: 4 mg

Weeks 9+: 6 mg (maintenance or escalate to 8-12 mg)

Best Practices:

Injection Sites: Arm > Abdomen > Thigh (absorption varies <7%)

Timing: Thursday PM (peaks weekends for appetite control)

Storage: Refrigerate (2-8°C); stable at ≤30°C for 28 days

🔹 Side Effect Management

Adverse Event
Incidence
Prevention/Treatment

Nausea
30%
– Ginger root 550 mg pre-dose
– Ramosetron 0.1 mg if severe

Diarrhea
24%
– Loperamide PRN
– Low-FODMAP diet

Mild Tachycardia (+6-8 bpm)
18%
– Monitor; usually resolves in 4-6 wks

Injection Reactions
9%
– Rotate sites weekly
– Hydrocortisone cream PRN

🔹 Who Benefits Most?
✅ Best Candidates:

BMI 30-45 with metabolic complications (prediabetes, NAFLD)

Non-responders to GLP-1/GIP dual agonists (e.g., tirzepatide)

Sarcopenic obesity (preserves muscle better than competitors)

🚫 Contraindications:

Medullary thyroid cancer (MTC) history

Pancreatitis (acute/chronic)

eGFR <30 (limited safety data)

🔹 Monitoring Requirements

Baseline: